CTOs on the Move

Capstone Development Services,

www.capstonedevservices.com

 
Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Beech Brook

Helping children & families thrive by promoting healthy child development, strengthening the ability to overcome adversity, & enhancing family health & stability.

Validation Professionals

Validation Professionals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

National Drug Source

National Drug Source is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Treace Medical Concepts

Treace Medical Concepts, Inc. brings revolutionary Hallux Valgus Surgery. A revolutionary approach to anatomic bunion correction. Call us today 904.373.5940.

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.